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component summary scores and clinical variables, at
baseline, week 2, and week 6, were observed. A similar
trend was observed between SF-12 and clinical variable
change scores at week 2 and week 6.
CONCLUSION: The SF-12 is a psychometrically sound
tool for the assessment of HQL in osteoarthritis patients.
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OBJECTIVE: To compare the responsiveness of arthritis-
specific and generic health outcome measures in relation
to changes in rheumatoid arthritis (RA) severity and to
treatment. Clinical trial patients (n = 315) were assessed
at baseline and again after two weeks of treatment. Crite-
rion measures of severity change included physician glo-
bal assessment, duration of morning stiffness, number of
tender and swelling joints, functional capacity classifica-
tion, visual analogue pain scale, and patient global assess-
ment.
METHODS: The responsiveness of each disease-specific
and generic measure was estimated independently using
the relative validity (RV) methodology, which compares
F-ratios for average changes in specific and generic mea-
sures across groups differing in the amount of change in
the criterion variables and treatment. RV coefficients esti-
mate how each measure responded, relative to the best
measure (RV = 1.0). An RA-specific measure was based
on the Health Assessment Questionnaire (HAQ). Generic
measures included eight scales, two summary measures,
and an arthritis-specific health index (ASHI) scored from
the SF-36 Health Survey.
RESULTS: The SF-36 ASHI was most valid (RV = 1.0)
for 4 of the 8 criteria. The SF-36 bodily pain (BP) scale
was most valid (RV = 1.0) for 2 of the 8 criteria, includ-
ing treatment. The SF-36 vitality scale was most valid
(RV = 1.0) for 1 of the 8 criteria. SF-36 scales measuring
physical health were consistently more valid (RV > .30)
than scales measuring mental health (RV < .20). The
HAQ was highly valid for 2 of the 8 criteria (RV = .89-
.92) and responded moderately well to 4 other criteria
(RV = .28-.49).
CONCLUSION: The responsiveness of the arthritis-spe-
cific scoring of the SF-36 health profile to changes in se-
verity of rheumatoid arthritis was equal to or better than
the generically scored SF-36 health profile and disease-
specific Health Assessment Questionnaire (HAQ).
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OBJECTIVE: To compare the responsiveness of arthritis-
specific and generic health outcome measures in relation
to changes in the severity of osteoarthritis (OA). Clinical
trial patients (n = 1,177) were assessed at baseline and
again after two weeks of treatment. Criterion measures of
change in severity included physician global assessment,
knee pain on weight bearing, knee pain on motion, and
patient global assessment.
METHODS: The responsiveness of each disease-specific
and generic measure was estimated independently using
the relative validity (RV) methodology, which compares
F-ratios for average changes in specific and generic mea-
sures across groups differing in the amount of change in
the criterion variables. RV coefficients estimate how each
measure responded, relative to the best measure (RV =
1.0). OA-specific measures were based on the WOMAC
questionnaire. Generic outcome measures included eight
scales, physical and mental summary measures, and ar-
thritis-specific health index (ASHI) scored from the SF-36
Health Survey.
RESULTS: The SF-36 ASHI was most valid (RV = 1.0)
for 3 of the 4 clinical criteria, followed by the SF-36
bodily pain (BP) scale (RV = .74-.98) for two of the clin-
ical criterion. SF-36 physical health (physical functioning,
role physical, physical summary) and social functioning
scales were consistently more valid (RV > .30) than the
SF-36 mental health scales (RV < .30). The WOMAC to-
tal scale score was more valid (RV = .91-1.0) than any of
the three WOMAC subscales. With the exception of the
SF-36 ASHI and BP scales, the WOMAC pain (RV =
.80-.83), physical functioning (RV = .76-.95), and stiff-
ness (RV = .61-.70) subscales were more valid than SF-36
scales.
CONCLUSION: This study replicates results from previ-
ous studies showing that arthritis-specific scoring of the
generic SF-36 health profile increases its responsiveness
to changes in arthritis severity.
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Key components of preventive health care for middle-
aged and older women include evaluating the risk for os-
teoporosis and coronary artery disease, considering hor-
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mane replacement therapy (HRT), and cancer screening.
HRT is effective for treating the symptoms of acute
menopause, and it may prevent some chronic health
problems associated with growing older. However, HRT
may increase the risks for other diseases.
OBJECTIVE: The purpose of this study was to estimate
the level of health care use and costs incurred by post-
menopausal women for conditions that have been associ-
ated with HRT.
METHODS: National health care survey and discharge
data were used to estimate health care use by women age
45 and older for cardiovascular disease, osteoporosis,
breast cancer, uterine cancer, and deep-vein thrombosis/
pulmonary embolism. The databases used were the
Healthcare Utilization Project-S, National Ambulatory
Medical Care Survey, National Hospital Ambulatory
Medical Care Survey, National Nursing Home Survey,
and National Home and Hospice Care Survey. Clinical
Classification for Health Policy Research codes were used
to identify patients whose primary diagnosis or procedure
corresponded with the above conditions. National
weights were used to estimate resource use. Treatment
costs were estimated using cost-to-charge ratios or Medi-
care Fee Schedule to calculate costs of individual proce-
dures.
RESULTS: For each of the five conditions, resource use
and costs are reported for hospitalization, outpatient,
nursing home, and home health care services. Resource
use and costs are also reported by age and race/ethnicity.
CONCLUSION: Results of the study may be used to esti-
mate the burden of disease for conditions commonly af-
fecting postmenopausal women and to provide data for
cost-effectiveness models comparing newly developed
drugs to existing HRTs.
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OBJECTIVE: To isolate the cost of bone fracture to a
Medicaid/Medicare payor for an osteoporosis-prone pop-
ulation.
SUBJECTS: Claims data for Georgia Medicaid eligibles
from 1992 through 1994 were obtained. Recipients meet-
ing the following inclusion criteria were retained for anal-
ysis: age 250 years, female, claim with an ICD9 code in-
dicative of fracture in 1993, 12 months of contiguous
eligibility immediately prior to and after first fracture
claim. Recipients were stratified based upon site of frac-
ture (femur/other fracture site).
METHODS: Amounts paid by Medicaid and Medicare
were proxies for direct medical costs. Per recipient per
month costs were disaggregated by category of service
(hospital, nursing home, physician, prescription, miscella-
neous) for each of the 24 months of the study. Inter-
rupted time series models were estimated to isolate the in-
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cremental change in cost due to fracture, with terms
controlling for pre-existing trend, run-in costs, and any
autoregressive errors.
RESULTS: A total of 765 subjects met inclusion criteria,
with 226 femur fracture patients. All times series models
estimated are significant, with R-squares ranging from
0.90 to 0.98. Average total cost temporarily increased
$1,120 and $1,091 for the month of femur and other
fracture, respectively. Observed cost increases returned to
baseline trend levels within three months after fracture.
Likewise, costs disagregated by category of service tem-
porarily increased with fracture, except nursing home
costs, which permanently increased after fracture.
CONCLUSION: Only nursing home costs increased per-
sistently over a 12-month period ensuing fracture; all
other costs increased but quickly returned to baseline
trend. The incremental direct total cost of any type of
fracture is less than $2,000. This is in contrast to the
$13,396 in outlays by Medicaid and Medicare the year
after fracture for the average fracture patient.
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Osteoporosis is a chronic degenerative disease with con-
centrated prevalence in the most rapidly growing segment
of the population, the elderly. Its clinical and economic
consequences are substantial. This study assesses the cost-
effectiveness of two gold standard therapeutic approaches
to reducing the impact of related fractures.
OBJECTIVES: To determine the cost-effectiveness ratios
of the two therapeutic approaches. To model the cohort
progression through the Markov states.
METHODS: Using published literature values, a Markov
model was constructed. The model depicts a cohort of
1,000 women progressing from age 50 to 90 years or
death, whichever comes first. The hormone therapy alter-
native includes calcium supplementation as part of the
regimen. The model accounts for the following confound-
ers: age dependent rate of death, predisposition to subse-
quent fracture, and the cardioprotective effect of hor-
mone therapy. Sensitivity analysis was conducted on all
relevant variables to assess the robustness of the findings.
The primary outcome of interest was cost per fracture
avoided. Additionally, Markov analysis of the model re-
ports the distribution of women across each Markov
state.
RESULTS: The study revealed that hormone therapy is
more cost-effective than calcium therapy. Cost-effective-
ness ratios for the two alternatives were $43,729.82 and
$87,003.53 per fracture avoided for hormone therapy
and calcium therapy, respectively. The incremental cost-
